| Document and Entity Information | Jan. 02, 2022 |
| Cover [Abstract] | |
| Amendment Flag | false |
| Entity Central Index Key | 0001867096 |
| Document Type | 8-K |
| Document Period End Date | Jan. 2, 2022 |
| Entity Registrant Name | XERIS BIOPHARMA HOLDINGS, INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-40880 |
| Entity Tax Identification Number | 87-1082097 |
| Entity Address, Address Line One | 180 N. LaSalle Street |
| Entity Address, Address Line Two | Suite 1600 |
| Entity Address, City or Town | Chicago |
| Entity Address, State or Province | IL |
| Entity Address, Postal Zip Code | 60601 |
| City Area Code | 1-844 |
| Local Phone Number | 445-5704 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.0001 per share |
| Trading Symbol | XERS |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
